VM:CC - Voyageur Pharmaceuticals Ltd Grants Deferred Share Units Compensation to Independent Directors
(TheNewswire)
Calgary, Canada – The Newswire – April 2, 2024- Voyageur Pharmaceuticals Ltd(TSXV:VM) (OTC: VYYRF) ("Voyageur" orthe "Corporation"), a provider of innovative medical imagingsolutions, on April 2, 2024, announces it issued 1,020,055 DeferredShare Units ("DSUs") to directors of the Company pursuant toits fixed 10% equity incentive compensation plan (the"Plan"). Each DSU represents a right of the holder toreceive one common share ("Common Share") of the Companyeffective as of the date that the holder ceases service as a directorof the Company. The DSUs are used to compensate directors of theCorporation for their annual retainers and are issued quarterly usinga deemed value that is equal to the weighted average share priceduring that quarter. The DSUs do not have an exercise price but inrespect of 628,255 DSU have a starting value equal to approximately$0.04974 per DSU, based on the weighted average share price for thequarter ended December 31, 2023 and in respect of 391,800 DSU have astarting value equal to approximately $0.07976 per DSU, based on theweighted average share price for the quarter ended March 31, 2024. TheDSUs are subject to the terms of the Plan and the policies of the TSXVenture Exchange (the "Exchange") and are subject toExchange approval. The DSUs and any Common Shares issued pursuant tothe exercise of the DSUs are subject to a four month hold inaccordance with the policies of the Exchange.
About Voyageur PharmaceuticalsLtd.
Voyageur, a Canadian public company trading under thesymbol VM on the TSX Venture Exchange, is in development of barium,iodine and carbon fullerene Active Pharmaceutical Ingredients (API)and high-performance, cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium, iodine andcarbon contrast imaging market, Voyageur aims to become a key playerby producing its own barium, iodine, and fullerene minerals anddrugs.
Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of its products byregulatory agencies worldwide. As the Corporation solidifies itspresence in the market, it will transition into a high-margin domesticmanufacturer of radiology drugs, further expanding its revenuestreams.
Voyageur is committed to sustainability andenvironmental stewardship. The Corporation envisions a future wherecarbon neutrality is the norm, and to achieve this, it plans to buildstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, itaims to become 100% carbon neutral across all its manufacturingactivities. Voyageur's commitment to the environment sets it apart asa pioneer in the industry.
At the core of the Corporation's operations, Voyageurowns a 100% interest in a barium sulphate (barite) project, theFrances Creek property. Additionally, Voyageur holds interests in ahigh-grade iodine, lithium, and bromine brine project situated inUtah, USA, further bolstering its position in the industry. Voyageuralso owns a 100% interest in two battery mineral projects which focuson copper/zinc development.
Voyageur's ambitious vision is to become the firstvertically integrated, carbon-neutral company in the imaging contrastmedia drug market. By controlling all primary input costs, from thesourcing of raw materials to final production, it plans to ensureunmatched quality and cost efficiency. Voyageur embodies the motto of" From the Earth to the Bottle ," highlighting itscommitment to responsible sourcing and manufacturing practices.
For Further Information:
Brent Willis, CEO, Albert Deslauriers, CFO,
Brent@vpharma.ca Albert@vpharma.ca
info@vpharma.ca https://voyageurpharmaceuticals.ca/
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Cautionary Statement Regarding “Forward-Looking” Information
This news release may contain certain forward-lookinginformation and statements, including without limitation, statementspertaining to approval by the Exchange for the DSU grants, statements relating to Voyageur's business plans, development ofcarbon neutral infrastructure, obtaining carbon neutrality, and otherstatements pertaining to business of Voyageur and the perceivedbenefits to Voyageur from certain business plans. All statementsincluded herein, other than statements of historical fact, areforward-looking information and such information involves variousrisks and uncertainties, including, without limitation, global marketfactors and supply chain issues, risks relating to the regulation andapproval of Voyageur's products, and general risks relating toVoyageur's business. There can be no assurance that such informationwill prove to be accurate, and actual results and future events coulddiffer materially from those anticipated in such information. Adescription of assumptions used to develop such forward-lookinginformation and a description of risk factors that may cause actualresults to differ materially from forward-looking information can befound in the Company's disclosure documents on the SEDAR+ website atwww.sedarplus.ca. Voyageur does not undertake to update anyforward-looking information except in accordance with applicablesecurities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.